Eli Lilly acquisition deals

What happened: Eli Lilly, the world's largest pharmaceutical company, is expanding its infectious disease portfolio through a series of acquisitions. On May 7, the company announced deals to buy three private vaccine makers—CureVac, LimmaTech Biologics, and Vaccine Company—for nearly $4 billion in cash. This follows Eli Lilly's largest bond issuance to date, a $9 billion investment-grade debt sale on the same day, primarily to fund these acquisitions. The company's head of business development, Jacob Van Naarden, hinted at more M&A activity, suggesting Eli Lilly is eager to push into new areas.

Market impact: Eli Lilly's stock (LLY) surged following the announcements, with the relative strength index (RSI) reaching the late 60s, indicating the stock is approaching overbought territory. Analysts have responded positively, with Guggenheim raising its price target for LLY due to the company's growth prospects. The pharmaceutical sector, particularly vaccine and infectious disease-focused companies, may see increased investor interest and potential M&A activity.

What to watch next: Eli Lilly's upcoming earnings reports (Q2 2023 on July 27) will provide insights into the financial impact of these acquisitions. Additionally, regulatory decisions regarding the acquired companies' vaccine candidates, such as CureVac's COVID-19 vaccine, will be crucial for evaluating the success of these deals. Lastly, investors should monitor Eli Lilly's RSI to determine if the stock's recent gains are sustainable or if a pullback is imminent.